Equity Overview
Price & Market Data
Price: $3.16
Daily Change: -$0.05 / 1.58%
Range: $3.15 - $3.26
Market Cap: $270,431,232
Volume: 339,138
Performance Metrics
1 Week: -0.63%
1 Month: 23.92%
3 Months: 2.60%
6 Months: 7.48%
1 Year: -19.39%
YTD: -5.67%
Company Details
Employees: 56
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.